Is nintedanib/Vigat considered a targeted drug and which patients are it suitable for?

Nintedanib (Nintedanib) is an oral small molecule multi-target tyrosine kinase inhibitor. Its mechanism of action is mainly through inhibiting signaling pathways such as vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and fibroblast growth factor receptor (FGFR), thereby intervening in pathological angiogenesis and fibrosis processes. Because it acts directly on a specific tyrosine kinase, nintedanib can be classified as a targeted agent. Compared with traditional non-specific anti-fibrosis drugs, targeted drugs have a clearer mechanism of action and can directly affect the pathological aspects of the disease, thereby achieving the effect of slowing down the progression of the disease.

Nintedanib is mainly suitable for patients with idiopathic pulmonary fibrosis (IPF), as well as some people with pulmonary fibrosis caused by connective tissue diseases or other interstitial lung diseases. Clinical guidelines recommend that nintedanib can be used in adult patients with significant decline in lung function or high disease activity, especially for patients with limited previous use of traditional anti-fibrosis treatments or patients with a high risk of progression. Its main advantage is that it can slow down the decline of lung function and improve the long-term prognosis of patients.

Regarding treatment tolerability and safety, nintedanib should be used with caution in patients with abnormal hepatic function or gastrointestinal disease. Doctors usually assess the patient's liver function, kidney function and blood pressure before taking medication, and develop an individualized dose based on the patient's specific physical conditions. It should be noted that nintedanib is not suitable for pregnant and lactating women, so women of childbearing age need to take effective contraceptive measures and avoid breastfeeding.

As a targeted drug, the advantage of nintedanib is that it can intervene in key signaling pathways in the process of fibrosis. Compared with non-specific drugs, targeting makes it more scientifically based in delaying disease progression and improving quality of life.

Reference materials:https://en.wikipedia.org/wiki/Nintedanib